GLUT4 upregulation on Naringin pretreatment.

<p>Immunofluorescence assay visualized upregulation of GLUT4 in differentiated L6 myoblast. High resolution confocal images (40X) of Untreated L6 myotubes, L6 myotubes treated with TBHP, Rosiglitazone (100 nM) and Naringin (100 μM, 24 h). Scale bar corresponds to 10μM. Each value represents mean ± SD (standard deviation) from triplicate measurements (n = 3) of three different experiments. Significance test between various groups were determined by using one way ANOVA followed by Duncan’s multiple range test. <b>*</b> P≤0.05 versus control; #P≤0.05 versus TBHP.</p

Intracellular ROS production and Fluorescence intensity analysis in L6 myoblast.

<p>(A) Fluorescence images (20 X magnifications) of untreated cell (i); Figures (ii), (iii) & (iv) represents cells induced with TBHP at 1, 10 & 100 μM; (v) Represents the relative fluorescence intensity analysis by BD Image Data Explorer software. Significance test between various groups was determined by using one way ANOVA followed by Duncan’s multiple range test. *P≤0.05 versus control. (B) Figure (i), (ii), (iii), (iv) & (v) represents fluorescence images of untreated cells, cells induced with TBHP (100 μM) and cells pretreated with Naringin (1, 10 & 100 μM) for 3h respectively; (vi) Represents the relative fluorescence intensity analysis by BD Image Data Explorer software. Significance test between various groups was determined by using one way ANOVA followed by Duncan’s multiple range test. *P≤0.05 versus control; #P≤0.05 versus TBHP.(C) Figure (i), (ii), (iii), (iv) & (v) represents fluorescence images of untreated cells, cells induced with TBHP (100 μM) and cells pretreated with Naringin (1, 10 & 100 μM) for 24h respectively; (vi) Represents the relative fluorescence intensity analysis by BD Image Data Explorer software. Scale bar corresponds to 87 μM. TBHP: Tertiary butyl hydrogen peroxide; Na1+TBHP, Na2+TBHP & Na3+TBHP represents relative fluorescence intensity analysis of cells pretreated with Naringin (1, 10 & 100 μM) followed by induction of TBHP; Each value represents mean ± SD (standard deviation) from triplicate measurements (n = 3) of three different experiments. Significance test between various groups was determined by using one way ANOVA followed by Duncan’s multiple range test.* P≤0.05 versus control; #P≤0.05 versus TBHP.</p

Antiglycation activity of Naringin.

<p>Antiglycation activity of Naringin at three different concentrations (1, 10 & 100 μM). Ascorbic acid was used as standard. Each value represents mean ± SD (standard deviation) from triplicate measurements (n = 3) of three different experiments.</p

Fluorescence analysis of 2-NBDG uptake by flow cytometry.

<p>FACS analysis of 2-NBDG uptake in differentiated L6 cells by plotting cell count against FITC revealed that 8%, 8.1% and 30% of cells uptake 2-NBDG in control, TBHP and Rosiglitazone treated cells respectively whereas 30.6%, 33.1%, 28%, 32% of cells uptake 2-NBDG, pretreated with two different concentrations (10 and 100 μM) of Naringin along with/without TBHP respectively. Each value represents mean ± SD (standard deviation) from triplicate measurements (n = 3) of three different experiments. Significance test between various groups was determined by using one way ANOVA followed by Duncan’s multiple range test.<b>*</b> P≤0.05 versus control.</p